|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select publications
Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract
Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract
Harries M et al. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J Clin Oncol 2005;23(31):7768-71. No abstract available
Holmes FA et al. Feasibility of testing core needle breast biopsies ex vivo in the ChemoFx® assay: Substudy results from US oncology trial 02-103. San Antonio Breast Cancer Symposium 2006;Abstract 5100.
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract
Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.
Robert N et al. Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 2073.
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin, and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presentation. San Antonio Breast Cancer Symposium 2006;Abstract 52.
 |
 |
